IO Biotech, Inc. (IOBT)
(Delayed Data from NSDQ)
$1.48 USD
-0.05 (-3.27%)
Updated May 3, 2024 03:59 PM ET
After-Market: $1.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
IOBT 1.48 -0.05(-3.27%)
Will IOBT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IOBT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOBT
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IOBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IOBT
IO Biotech Board Member Jack Nielsen Resigns Due to Health
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
IO Biotech participates in a conference call with Jefferies
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech appoints Shamsaei as SVP, Commercial Development